# Anvisa bans sales of irregular medicines in Brazil > The bans cover insulin distributed without authorization, an improperly compounded product and unregistered peptides, as well as two medicine batches with quality issues. - Canonical URL: https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026 - Publisher: Newsverum - Section: Health - Country: Brazil - Published: 2026-10-06T17:11:49+00:00 - Updated: 2026-10-07T00:55:00+03:00 - Event / data period: 2026-10-06 - Other editions: [Türkçe](https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026.md), [العربية](https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026.md), [Français](https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026.md), [Español](https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026.md), [Deutsch](https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026.md), [Português](https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026.md) Brazil’s health regulator Anvisa banned the sale of several irregular medicines on October 6. The measures cover insulin glargine distributed by a company without authorization, a compounded medicine marketed to the public without prescriptions, and unregistered peptides. Anvisa also reported a manufacturer’s voluntary recall of one Imaavy batch and ordered a recall of one Lizbi antibiotic batch after confirming loss of sterility linked to compromised packaging. This account reports regulatory actions and is not individual treatment advice. ## Data ### Medicines prohibited or recalled Products and action types in Anvisa’s October 6, 2026 notice. Methodology: The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance. | Product or category | Anvisa action | |---|---| | Insulin glargine 3 mL/100 IU, Costa Mar | Sale of all lots prohibited; distributor lacked authorization. | | Vermefree compounded medicine, Sintonia Pharma | Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription. | | Unregistered peptides listed in notice | Sale, manufacture, distribution, advertising, transport and use prohibited. | | Imaavy batch JNYJ1201 | Voluntary recall reported; possible glass particles in vials. | | Lizbi batch 0000207107 | Recall ordered after confirmed sterility loss linked to compromised primary packaging. | Sources: · Download data: [JSON](https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=en&format=json) · [CSV](https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=en&format=csv) ## Sources - [National Health Surveillance Agency of Brazil]() (Source checked: 2026-10-06; Published: 2026-10-06) ## Correction history - 2026-10-07T00:55:00+03:00: German and Portuguese editions and translations of the data and correction explanations have been added to this article. --- Cite the canonical URL above. [Editorial standards and corrections](https://newsverum.com/en/editorial)